It is with severe despondency and disappointment we hereby inform that we have decided to cancel the 4th NordiQC International conference planned 2-5th of June 2020.
The global uncertainty and extensive travel restrictions related to covid-19 have had a tremendous impact on registrations for the conference, which has been status quo for more than 3 weeks now. The uncertainty has unfortunately and of central decisive importance for the cancellation also affected many of our speakers not being able to provide a definite confirmation of their presence. At present the incidence rate increases dramatically in Denmark and Europe and expected to continue with more restrictions to come concerning travel and meetings. We hereby have been put in a very risky situation to either postpone the cancellation of the conference to last minute due to no improvements for the covid-19 epidemic or to have a conference with a very reduced number of participants/speakers and hereby an abridged scientific meeting compared to the level expected from all stakeholders of our conference.
We hope that the conclusion to cancel the conference at this point is considered as due diligence, as we want to reduce the uncertainty and negative impacts related to the decision.
NordiQC reimburses all registration fees and sponsorship payments. If payment has been performed by bank account transfer, please send bank account data to us with registration number, IBAN and SWIFT codes.
Please receive our deepest apologies for all inconveniences.
NordiQC welcomes pathologists, technologists, scientists, diagnostic company staff members and others with interest in applied immunohistochemistry (IHC) to join the
4th NordiQC Conference on Applied Immunohistochemistry
arranged in collaboration with the
International Society for Immunohistochemistry and Molecular Morphology
Introduced by international experts and NordiQC specialists, the conference is focused on development and standardization of IHC and related molecular based techniques for tumour classification and precision medicine. Issues of IHC protocol optimization, selection and interpretation of positive and negative controls, and external quality assessment (EQA) / proficiency testing will be highlighted. Special emphasis is given on up-to-date pathological approach to new diagnostic and predictive biomarkers, particularly in tumours of breast, lung, digestive system, kidney, urinary tract, prostate, testis and soft tissues.
IHC is an increasingly important ancillary tool in diagnostic pathology, but IHC is far from standardized. We must devote our efforts to developing international standards in our daily practice as well as in science for the overall benefit of patients. As the role of IHC is changing from an ancillary diagnostic technique to that of a stand-alone diagnostic method, the results of which determine treatment approach, standardization of preanalytical, analytical and postanalytical methods have become even more important, as the results emanating from different laboratories must be directly comparable.
This conference gives you the opportunity to learn about real-world, practical applications in the ever-evolving field of applied immunohistochemistry.
Welcome to Aalborg
|Søren Nielsen||Mogens Vyberg||Lilli Guldager Malaca|
|NordiQC scheme director||NordiQC conference director||NordiQC conference secretary|
|e-mail: email@example.com||e-mail: firstname.lastname@example.org||e-mail: email@example.com|
|Aalborg University Hospital||Aalborg, Denmark||www.nordiqc.org|
Registration site: http://aalborg-convention.dk/registration/NordiQC2020
Preliminary NordiQC_programme 2020 (Updated 3rd January 2020)
The speakers’ CV and abstracts will be uploaded around 1st March 2020.
Also see the programme, abstracts etc. from the 3rd NordiQC conference on:
http://nordiqc2020.dk/wp-content/uploads/NordiQC_Conference_programme_2020_30.09.2019.docxClick on Speakers and select a speaker to open and download presentations (pdf-files)